Expert perspectives on the prevention and treatment of tumor lysis syndrome (TLS) in patients on therapy for cancer.
EP. 1: Overview on Tumor Lysis Syndrome: Incidence and Risk Factors
Key opinion leaders James Short, MD, and John Reagan, MD, share an overview on the incidence and clinical risk factors of tumor lysis syndrome.
EP. 2: Identification of Tumor Lysis Syndrome: Signs and Symptoms
Comprehensive insight on the signs and symptoms that help lead to the identification of tumor lysis syndrome in patients receiving therapy for cancer.
EP. 3: Role of a Multidisciplinary Healthcare Team to Manage Tumor Lysis Syndrome
Shared insight on the multidisciplinary management of tumor lysis syndrome and how treatment planning may be adjusted after it is identified.
EP. 4: Prophylactic Measures to Prevent Tumor Lysis Syndrome
Expert perspectives on prophylactic measures to prevent tumor lysis syndrome in patients receiving therapy for cancer.
EP. 5: Guideline-Directed Treatment Options for Tumor Lysis Syndrome
James Short, MD, and John Reagan, MD, highlight guideline-indicated treatment options for patients with or at risk of tumor lysis syndrome.
EP. 6: Tumor Lysis Syndrome: Clinical Implications of Prophylaxis and Treatment
Experts James Short, MD, and John Reagan, MD, share comprehensive insight on the clinical implications of treating TLS in patients receiving therapy for cancer.
EP. 7: TLS Management in Academic vs Community Centers of Care
A brief review of the differences that might be observed between tumor lysis syndrome management in an academic versus community setting.
EP. 8: Tumor Lysis Syndrome: Unmet Needs and Future Directions in Care
Closing out their discussion on tumor lysis syndrome management, James Short, MD, and John Reagan, MD, highlight unmet needs and future evolutions in the treatment landscape.
EP. 9: An Overview on Tumor Lysis Syndrome in Cancer Care
Anthony Perissinotti, PharmD, BCOP, highlights associated risk for tumor lysis syndrome and identifies signs and symptoms.
EP. 10: Role of a Pharmacist in Managing Tumor Lysis Syndrome
Expert perspective on the role of a pharmacist in managing patients with identified tumor lysis syndrome.
EP. 11: Tumor Lysis Syndrome: Prophylactic Strategies
An overview of the prophylactic strategies that may be utilized to reduce the likelihood of tumor lysis syndrome.
EP. 12: Tumor Lysis Syndrome: Treatment Armamentarium
Guideline-directed treatment strategies available to patients with identified tumor lysis syndrome.
EP. 13: Practical Advice on the Management of Tumor Lysis Syndrome
Closing out his discussion on tumor lysis syndrome, Anthony Perissinotti, PharmD, BCOP, shares practical advice on its identification and management.
MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma
Locally Produced CAR T-Cell Therapy Elicits 92% ORR in Relapsed/Refractory Myeloma
Dr Dhakal on Survival and Safety Outcomes With Cilta-Cel in R/R Myeloma
Dr Corre on MRD Negativity With D-VTd Induction/Consolidation in Newly Diagnosed Multiple Myeloma